Gujarat Magazine

ABVC BioPharma’s ABV-1504 market size expected to increase many folds by 2032, report DelveInsight

 Breaking News
  • No posts were found

ABVC BioPharma’s ABV-1504 market size expected to increase many folds by 2032, report DelveInsight

January 23
18:06 2024
ABVC BioPharma’s ABV-1504 market size expected to increase many folds by 2032, report DelveInsight
ABV-1504 market

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on ABV-1504 (ABVC BioPharma) providing insights into the drug market landscape and market forecast of ABV-1504 upto 2032. The report, titled ABV-1504 Market Size, Forecast, and Emerging Insight − 2032″ is now available for review and analysis.

Are you interested in finding out the projected market size of ABV-1504 in 2032? Click @ ABV-1504 Market Size

The ABV-1504 Market Report offers projected sales forecasts for ABV-1504 for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Do you know your drug’s competitive positioning against ABV-1504? Download Report: ABV-1504 Market Dynamics

ABVC BioPharma’s ABV-1504 is serving as a beacon of hope for the patients suffering from the Major Depressive Disorder. ABV-1504 is a promising pharmaceutical development primarily intended for the treatment of Major Depressive Disorder. This innovative drug operates through its unique mechanism of action as a Norepinephrine Transporter (NET) Inhibitor. The collaborative efforts behind ABV-1504 involve Stanford University in the United States and Taipei Veterans General Hospital in Taiwan. As of 2023, the drug has successfully completed Phase II Trial Part II and is poised to enter the crucial End of Phase II (EOP2) meeting with the FDA. Notably, ABV-1504 has secured patents in key countries such as the United States, the United Kingdom, Japan, Germany, France, Italy, China, and Taiwan. Its favorable toxicology profile, with negative genotoxicity and a NOAEL of 3,000mg/kg/day in rats and dogs, underscores its safety. The drug’s clinical journey includes the completion of a Phase II Clinical Study Report (CSR) in 2019, further supporting its potential efficacy and safety in the realm of depressive disorder treatment.

The report extensively covers the details and developments related to ABV-1504, capturing important highlights on developmental pipeline, regulatory status and special designations of ABV-1504, route of administration, safety and efficacy details.

ABV-1504 Market Assessment

This ABV-1504 market report provides a detailed market assessment of ABV-1504 for Major Depressive Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

ABV-1504 Clinical Assessment

The report provides information related to clinical trials of ABV-1504 for Major Depressive Disorder covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related. 

ABV-1504 Competitive Landscape 

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the ABV-1504.

ABV-1504 Market Size in the US

A dedicated section of the report focuses on the expected market size of ABV-1504 for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

What is a ABV-1504 Prescribed for?

ABV-1504 is prescribed for the treatment of Major Depressive Disorder.

Key Highlights of ABV-1504: 

  • The report contains forecasted sales of ABV-1504 for indication till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Major Depressive Disorder.
  • The report also features the qualitative and quantitative analysis with analysts as well as KOL views for ABV-1504 in Major Depressive Disorder.

Why you should buy ABV-1504 Market Report:

  • The report provides future market assessments for ABV-1504 for Major Depressive Disorder in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
  • Leading ABV-1504 for Major Depressive Disorder forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABV-1504 
  • Discover the competitive landscape of ABV-1504 through 7MM
  • Get a Thorough Analysis of the ABV-1504 Development pipeline, Safety & Efficacy of the ABV-1504, and ROA
  • Thorough ABV-1504 market forecast will help understand how drug is competing with other emerging ABV-1504
  • Get analysis of the ABV-1504 clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
  • Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Request for Sample Page @

Related Reports By DelveInsight:

Major Depressive Disorder Market

DelveInsight’s Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Major Depressive Disorder Pipeline

DelveInsight’s, “Major Depressive Disorder Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States